



Interim Report January - June 2009

Increased profit by guaranteed extraordinary revenue

- **Net sales** for the interim period amounted to 35.4 million SEK (35.7) and for the second quarter to 19.5 million SEK (20.9).
- **EBIT** for the interim period amounted to 8.9 million SEK (4.9) and for the second quarter to 6.8 million SEK (3.5), and increase of 81 per cent for the interim period.
- **Profit after tax** for the interim period amounted to 7.2 million SEK (4.2) and for the second quarter to 5.1 million SEK (2.8).
- **After tax earnings per share** for the interim period amounted to 0.77 SEK (0.45) and for the second quarter to 0.54 SEK (0.30).
- **Cash flow** for the interim period amounted to 9.2 million SEK (5.5) and for the second quarter to 5.8 million SEK (4.5).
- The supply agreement with Kraft is discontinued, which released a guaranteed extraordinary revenue of 5.4 million SEK during the second quarter.
- Launch of a new immune range during the second half of the year in cooperation with Skånemejerier.
- Deepened cooperation with NextFoods, that is launching a high concentrated probiotic drink in USA.
- Continuous positive sales of ProViva.
- Probi forecasts EBIT and cash flow to be positive in 2009.

CEO's comments:

"The guarantee payment, which we have received from Kraft, gives us an extraordinary large profit during the second quarter. Even if the income from Kraft disappears now, at least temporarily, there are all reasons to see the future optimistically. We are launching a new immune range together with Skånemejerier, we are deepening the cooperation with NextFoods and launching a new product together with them.", says Michael Oredsson, CEO of Probi.

For further information, please contact:

Michael Oredsson, CEO Probi, phone: +46 46 286 89 23 or +46 707 18 89 30
e-mail: michael.oredsson@probi.se

Distributed Aug 19th, 2009. 09.00 (CET)

About Probi

Probi is a leading player in the field of probiotic research and development of effective and well-documented probiotics. The research areas are: stomach and gastrointestinal tracts, immune defense, metabolic disorders as well as stress and recovery. Probi's customers are leading companies within the business areas Functional Food and Dietary Supplements. The company's total operating income was 69.4 million SEK 2008, consisting mostly of royalty revenues. Probi's shares are listed on the Nordic List of the Stockholm Stock Exchange, Small Cap and has approximately 4.000 shareholders. Visit www.probi.com

